Privately-held US genome-scale drug discovery company Orionis Biosciences has announced a second multi-year collaboration ...

The partnership will include $105m upfront to Orionis, with the potential for further payments that could exceed $2bn.

Orionis Biosciences Inc. is sticking with Genentech Inc. in a second deal to discover small-molecule monovalent glue therapies for treating cancer. Privately held Orionis is getting $105 million up ...

Roche (RHHBF) unit Genentech partners Orionis Biosciences to develop and commercialize cancer drugs in a deal that exceed $2B ...

Roche, along with Bristol Myers Squibb, Novo Nordisk, AbbVie, Eli Lilly and others, is making inroads into molecular glues to ...

Genentech signs $105M upfront deal with Orionis Biosciences to develop molecular glue cancer drugs, with potential milestones ...

Roche's Genentech is sticking with Orionis Biosciences, handing over $105 million upfront as part of its second deal with the ...

SIMO, a leader in innovative connectivity solutions, announced today the upcoming launch of its next-generation mobile hotspots: Solis Hero and Solis Pro. Building on the legacy of the Solis Lite and ...

Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches to precision T cell activation, today announced the appointment of Everett E. Vokes, M.D., to its ...

Orionis Biosciences, a privately held, clinical-stage life sciences company focused on the rational discovery and development of drug modalities with induced proximity mode of action, today announced ...

Genentech, part of the Roche Group and led by Ashley Magargee, announced a massive $50 billion commitment to biotech manufacturing and research. 16. AbbVie, with Rob Michael at the helm ...